Coronado Biosciences Receives Orphan-Drug Designation From FDA for CNDO-109-Activated Allogeneic Natural Killer Cells for the Treatment of AML

BURLINGTON, Mass., June 19, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to CNDO-109-Activated Allogeneic Natural Killer Cells (CNDO-109) for “the treatment of acute myeloid leukemia (AML).”